Imaging for early stage breast cancer

Randomized Trial of Accelerated Partial Breast Irradiation, The RAPID trial

Primary endpoint: IBTR, assumed 1.5% at 5 yr with WBI Secondary endpoints: adverse cosmesis, RT toxicity, QoL, DFS, event-free survival, OS Study design: non-inferiority, accept up to max 1.5% increase in IBTR at 5 yr, interim planned at 30 and 50 IBTR, not reached

This report is data from a pre- planned interim analysis of global cosmetic score

Olivotto et al, JCO 2013